CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out

Detailed summary
CG Oncology said Monday its experimental bladder cancer treatment cut the risk of recurrence by 68%. The biotech stock broke out. The post CG Oncology Exceeds Even The 'Most…
CG Oncology (CGON) said Monday its experimental bladder cancer treatment cut the risk of recurrence by 68%. The news sent the biotech stock flying into breakout territory. "We see these results as meaningfully exceeding both the powering expectations (~30%) and investor expectations (~40%), and even in our most bullish conversations we did not hear investors expect a risk reduction greater…
Opening of the article, excerpted from Investor's Business Daily. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)